Skip to main content

ADVERTISEMENT

Josh Howell, PharmD, BCOP

Letters to the Editor
10/20/2021
Aimee Ginsburg, PharmD, BCPS
Leslie Busby, MD
Kaci Dominguez, PharmD
Josh Howell, PharmD, BCOP
Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.
Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.
Aimee Ginsburg, PharmD, BCPS,...
10/20/2021
Journal of Clinical Pathways